(Q51103968)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

editorial

0 references

title

Will longer antimicrobial patents improve global public health? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Julie Balch Samora

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Karen Keller-Cuda

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

559-566

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Lack of development of new antimicrobial drugs: a potential serious threat to public health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

The antibiotic pipeline--challenges, costs, and values

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Trends in antimicrobial drug development: implications for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Antimicrobial drug development--the past, the present, and the future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Novel streptogramin antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Chemotherapy for gram-positive nosocomial sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

The streptogramin antibiotics: update on their mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

The emerging new generation of antibiotic: ketolides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Synthesis and antibacterial activity of novel C12 vinyl ketolides.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Tigecycline: a novel glycylcycline antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Tigecycline: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Tigecycline: first of a new class of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

1 reference

7 January 2021

Tigecycline: a novel glycylcycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Pharmacoeconomics of treatment with the newer anti-Gram-positive agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Clinical experience with recently approved antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Can patents deter innovation? The anticommons in biomedical research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

An economic perspective on policy to reduce antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

How property rights and patents affect antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Vancomycin-resistant enterococci: colonization, infection, detection, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Antimicrobial use in animal feed--time to stop.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Return of chloroquine antimalarial efficacy in Malawi.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Scrooge and intellectual property rights

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Patent buy-outs for global disease innovations for low- and middle-income countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

Why is big Pharma getting out of antibacterial drug discovery?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970188-3

7 January 2021

10.1016/S1473-3099(07)70188-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17646029%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference